Goods & Services

Biological preparations for the treatment of cancer; biological preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in chemotherapy; anti-cancer preparations; pharmaceutical preparations for use in stimulating white blood cell production.

Goods & Services

(1) Biological preparations for the treatment of cancer; biological preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in chemotherapy; anti-cancer preparations; pharmaceutical preparations for use in stimulating white blood cell production

Goods & Services

(1) Biological preparations for the treatment of cancer; biological preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in chemotherapy; anti-cancer preparations; pharmaceutical preparations for use in stimulating white blood cell production

Goods & Services

pharmaceuticals, namely, oral contraceptives; oral hormonal contraceptives; contraceptive preparations; hormone replacement therapy preparations; hormonal agents for treating disorders and conditions related to women's health, namely, symptoms and conditions associated with menopause, pre-menstruation syndrome and other symptoms and conditions associated with menstruation; transdermal patches featuring contraceptive preparations

Goods & Services

pharmaceuticals, namely, oral contraceptives; oral hormonal contraceptives; contraceptive preparations; hormone replacement therapy preparations; hormonal agents for treating disorders and conditions related to women's health, namely, symptoms and conditions associated with menopause, pre-menstruation syndrome and other symptoms and conditions associated with menstruation

Goods & Services

pharmaceuticals, namely, oral contraceptives; oral hormonal contraceptives; contraceptive preparations; hormone replacement therapy preparations; hormonal agents for treating disorders and conditions related to women's health, namely, symptoms and conditions associated with menopause, pre-menstruation syndrome and other symptoms and conditions associated with menstruation; transdermal patches featuring contraceptive preparations

Abstract

The present invention relates to a stable pharmaceutical composition comprising methylnaltrexone or its pharmaceutically acceptable salts. The invention provides an alternative methylnaltrexone composition for oral administration for the effective treatment of opioid-induced constipation (OIC). The present invention further relates to compositions comprising methylnaltrexone or its pharmaceutically acceptable salts and docusate sodium, as well as processes for their preparation. The compositions provide the desired immediate release of methylnaltrexone and exhibit stability under accelerated storage conditions. The compositions are administered orally once daily for the treatment of opioid-induced constipation in adult patients with cancer or chronic non-cancer pain. Additionally, the invention provides methylnaltrexone compositions for oral administration that are bioequivalent to the currently marketed Relistor® tablets.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/225 - Polycarboxylic acids

Goods & Services

Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension, interstitial lung disease, and idiopathic pulmonary fibrosis.

Abstract

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

IPC Classes  ?

• C07D 498/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 487/10 - Spiro-condensed systems
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• C07D 491/20 - Spiro-condensed systems
• C07D 498/20 - Spiro-condensed systems

Abstract

The invention relates to stable oral formulations of pimavanserin or its pharmaceutically acceptable salts, provided in the form of ready-to-use liquids, powders for reconstitution, orally dispersible tablets, and kits containing pre-measured powder and a liquid vehicle for reconstitution. These formulations are stable for longer periods and are palatable, thereby improving patient compliance and adherence in the treatment of psychosis associated with Parkinson's disease.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 9/107 - Emulsions
• A61K 9/28 - DrageesCoated pills or tablets
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a stable pharmaceutical composition comprising valbenazine or its pharmaceutically acceptable salts or derivatives thereof, and a pharmaceutically acceptable carrier for the treatment of patients suffering from tardive dyskinesia, and chorea associated with Huntington disease. The invention further relates to oral liquid stable compositions of valbenazine or its pharmaceutically acceptable salts or derivatives thereof. These compositions demonstrate stability throughout both the manufacturing process and their shelf life. Oral liquid compositions of the present invention are advantageous due to their straightforward manufacturing process and consistent functionality. Furthermore, the said liquid oral compositions are designed to provide a pleasant taste, thereby promoting better patient compliance and facilitating administration. The compositions of the present invention are suitable to administer via nasogastric, gastrostomy, or other enteral tubes.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

A novel process for processing micronized active pharmaceutical ingredients (API) to improve the crystallinity of the micronized API. The process involves the treatment of micronized API with water to improve the crystallinity of the API without impacting the particle size of the API. The process of the invention involves the treatment of micronized API such as Fluticasone Furoate with water or treatment with water vapor exposure process to reduce the amorphous content in the micronized API without altering the nature of particle size, crystallinity, and the morphology of API.

IPC Classes  ?

• C07J 31/00 - Normal steroids containing one or more sulfur atoms not belonging to a hetero ring

Abstract

The invention provides a process for manufacturing certolizumab pegol from bacterial host cells. The invention provides refolding process of certolizumab wherein the solubilized solution of heavy chain and light chain of certolizumab is treated with refolding buffer under suitable conditions including pII, temperature, and incubation period to obtain high quality and quantity of refolded protein. The invention further provides efficient pegylation process to obtain certolizumab pegol in good yields.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The present invention relates to stable composition of edaravone intended for human oral administration in the form of an aqueous suspension. The invention further relates to an economic, easy to prepare and patient compliant edaravone suspension with improved stability.

IPC Classes  ?

• A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/08 - Solutions
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention provides the following aspects, subject matters, and preferred embodiments, which respectively taken alone or in combination, contribute to fulfill the object of the present invention. The invention provides stable nasal compositions including Rizatriptan or its pharmaceutically acceptable salts thereof. More specifically, the invention provides the low dose stable compositions of Rizatriptan or its pharmaceutically acceptable salts thereof. As per the important aspect of the invention, the inventors have provided the stable compositions containing one or more permeation enhancers, solvent(s) and/or co-solvent(s) or a combination thereof and other pharmaceutically acceptable excipients that provide the enhanced bioavailability of the drug. According to another aspect of the current invention, the stable nasal compositions of Rizatriptan or its pharmaceutically acceptable salts thereof containing relative quantities of permeation enhancers and solvent(s) and/or co-solvent(s) or a combination thereof are provided.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The present invention provides oral pharmaceutical compositions of tenofovir alafenamide succinate, polymorph, cocrystal thereof, alone or in combination with one or more anti-viral drug and one or more pharmaceutically acceptable excipients. The present invention provides oral pharmaceutical compositions of tenofovir alafenamide succinate in combination with one or more anti-viral drug and one or more pharmaceutically acceptable excipients.

IPC Classes  ?

• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
• A61K 47/02 - Inorganic compounds
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The present invention discloses a pharmaceutical formulation of antibodies or antigen-binding fragments against PD1, comprising anti-PD1 antibody, buffer and chelating agent and a method for preparing the same. The disclosed formulation is a stable formulation and suitable for parenteral route of administration. The formulation is citrate free and capable of reducing the degradants in the composition at antibody concentration up to 100 mg/ml.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to stable ophthalmic pharmaceutical formulations of aflibercept in a concentration ranging from 10mg/ml to 400mg/ml and one or more pharmaceutically acceptable excipients selected from buffer, stabilizing agents and surfactant.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to stable ophthalmic pharmaceutical formulations of aflibercept in a concentration ranging from 10mg/ml to 400mg/ml and one or more pharmaceutically acceptable excipients selected from buffer, stabilizing agents and surfactant.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to stable aqueous ready-to-dilute compositions of dalbavancin or physiologically acceptable salts thereof, which are suitable for intravenous administration. The aqueous formulation provides improved long-term stability upon storage and does not require reconstitution prior to administration. This application relates to stable aqueous dalbavancin compositions and its use in the treatment of bacterial infections.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 47/02 - Inorganic compounds
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The present invention relates to stable aqueous ready-to-dilute compositions of dalbavancin or physiologically acceptable salts thereof, which are suitable for intravenous administration. The aqueous formulation provides improved long-term stability upon storage and does not require reconstitution prior to administration. This application relates to stable aqueous dalbavancin compositions and its use in the treatment of bacterial infections.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 47/02 - Inorganic compounds
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against Interleukin 5 (IL-5) comprising buffer and one or more amino acids. The disclosed formulations are stable IL-5 antibodies formulations suitable for parenteral route of administration.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against Interleukin 5 (IL-5) comprising buffer and one or more amino acids. The disclosed formulations are stable IL-5 antibodies formulations suitable for parenteral route of administration.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The invention provides a stable topical cream formulation of clascoterone for treatment dermatological conditions. More particularly, the invention relates to a stable topical aqueous cream formulation of clascoterone wherein clascoterone drug is in solubilized form in the cream.

IPC Classes  ?

• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 9/10 - DispersionsEmulsions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 31/355 - Tocopherols, e.g. vitamin E

Abstract

A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - DispersionsEmulsions
• A61K 9/20 - Pills, lozenges or tablets
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Goods & Services

(1) Printed matter and publications namely articles, newsletters, flyers, magazines, and manuals in the medical, pharmaceutical, and healthcare fields. (1) Financial administration of patient reimbursement programs; financial services in the nature of payment processing services; providing financial support to patients for the purchase of medications (2) Support programs in the nature of providing medical counselling and medical information in the field of pharmaceuticals and safety issues pertaining to pharmaceuticals; providing medical information in the field of pharmaceuticals for the treatment of autosomal dominant polycystic kidney disease and safety issues pertaining to kidney disease pharmaceuticals via printed articles, newsletters, flyers, magazines, and manuals. (3) Providing patient advocate and support services in the field of treatment of diseases and disorders; providing personal support services for patients with autosomal dominant polycystic kidney disease and their families.

Abstract

The present invention relates to a process for producing a recombinant protein in a cell culture medium. comprising culturing mammalian cells expressing the protein of interest in a production medium at suitable conditions: and supplementing the production medium with feed components in such quantity that the residual carbon to nitrogen ratio is controlled. The present invention further relates to a process for producing a recombinant protein in a cell culture medium, wherein recombinant protein of interest has increased acidic variants and/or acidic variants and reduced basic variants.

IPC Classes  ?

• C12N 5/075 - OocytesOogonia
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention discloses a method for separation and analysis of highly glycosylated protein and its charge variants utilizing ion exchange chromatography. The method employs a novel elution method in which the ionic strength of the elution buffer is alternately increased and decreased after a fixed time interval to improve the separation and resolution of charge variants of the protein. In this method, first the ion exchange matrix is saturated up to 10% of the elution buffer, and then the elution buffer ionic strength increases by about 0.5% to about 2% every 2 minutes, then decreases to about 2% to about 5% every 2 minutes, and so on until the elution buffer ionic strength reaches 100%.

IPC Classes  ?

• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C07K 1/18 - Ion-exchange chromatography
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution

Abstract

This disclosure relates to pharmaceutical combinations for treating and/or preventing cancer and methods and uses thereof. More particularly, provided is a pharmaceutical combination comprising a SOS1 Inhibitor and an additional active ingredient selected from a KRAS inhibitor such as a KRAS G12C inhibitor and a KRASG12D inhibitor, KRAS G13C inhibitor, and panKRAS inhibitor; an EGFR inhibitor; an ERK1/2 inhibitor; a BRAF inhibitor; a pan-RAF inhibitor; a MEK inhibitor; a AKT inhibitor; a SHP2 inhibitor; protein arginine methyltransferases (PRMTs) inhibitor such as a PRMT5 inhibitor and Type 1 PRMT inhibitor; a PI3K inhibitor; a cyclin-dependent kinase (CDK) inhibitor such as CDK4/6 inhibitor; a FGFR inhibitor; a c-Met inhibitor; a RTK inhibitor; a non-receptor tyrosine kinase inhibitor; a histone methyltransferases (HMTs) inhibitor; a DNA methyltransferases (DNMTs) inhibitor; a Focal Adhesion Kinase (FAK) inhibitor; a Bcr-Abl tyrosine kinase inhibitor; a mTOR inhibitor; a PD1 inhibitor; a PD-L1 inhibitor; CTLA4 inhibitor; and chemotherapeutic agents such as gemcitabine, doxorubicin, cisplatin, carboplatin, paclitaxel, docetaxel, topotecan, irinotecan and temozolomide.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a stable pharmaceutical composition comprising methylnaltrexone and its pharmaceutically acceptable salts. The invention further relates to compositions comprising of methylnaltrexone and its pharmaceutically acceptable salts and ion exchange resin and its process of preparation. The compositions are substantially free of impurities. The compositions provide the desired immediate release of methylnaltrexone and were found to be stable under accelerated stability conditions. The compositions are administered orally once daily for the treatment of opioid-induced constipation in adult patients with cancer and chronic non-cancer pain.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/795 - Polymers containing sulfur

Abstract

The disclosed invention relates to a stable pharmaceutical composition of varenicline or pharmaceutically acceptable salts thereof. More specifically the disclosed invention relates to a pharmaceutical composition comprising varenicline pharmaceutically acceptable salts thereof with daily acceptable limit of nitrosamine impurities.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

The invention provides a process for manufacturing certolizumab pegol from bacterial host cells. The invention provides refolding process of certolizumab wherein the solubilized solution of heavy chain and light chain of certolizumab is treated with refolding buffer under suitable conditions including pH, temperature, and incubation period to obtain high quality and quantity of refolded protein. The invention further provides efficient pegylation process to obtain certolizumab pegol in good yields.

IPC Classes  ?

• C07K 1/14 - ExtractionSeparationPurification
• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Goods & Services

(1) Inhalers used for the treatment of respiratory ailments; inhalers filled with pharmaceutical preparations for the treatment of respiratory ailments.

Goods & Services

(1) Inhalers used for the treatment of respiratory ailments; inhalers filled with pharmaceutical preparations for the treatment of respiratory ailments.

IPC Classes  ?

• A61M 15/00 - Inhalators

Abstract

A breath actuated metered dose inhaler including a housing, a canister and a trigger mechanism. The trigger mechanism is activated by the inhalation of air which comprises of a diaphragm. The central rigid disk of the diaphragm is provided with the interlocking means to firmly secure and bound the peripheral flexible polymer ring with the central rigid disc. The mechanical interlock between a central rigid disk and a peripheral flexible polymer ring on the diaphragm prevent peripheral flexible polymer ring from being peeled off from the central rigid disc while the vacuum is being retained prior to inhalation.

IPC Classes  ?

• A61M 15/00 - Inhalators

Goods & Services

(1) Pharmaceuticals, namely, contraceptives, oral contraceptives, and oral hormonal contraceptives; contraceptive preparations and substances

Goods & Services

(1) Pharmaceutical preparations for use in pregnancy termination

Abstract

A breath actuated metered dose inhaler including a housing, a canister and a trigger mechanism. The trigger mechanism is activated by the inhalation of air which comprises of a diaphragm. The central rigid disk of the diaphragm is provided with the interlocking means to firmly secure and bound the peripheral flexible polymer ring with the central rigid disc. The mechanical interlock between a central rigid disk and a peripheral flexible polymer ring on the diaphragm prevent peripheral flexible polymer ring from being peeled off from the central rigid disc while the vacuum is being retained prior to inhalation.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61M 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

Provided herein are new devices for indicating the status of events, such as the number of relevant events that are remaining and/or that have already occurred up to the present moment and to related devices, systems, and methods. In some aspects, the event-related indicator devices of the invention are used within larger dispensing devices or systems, e.g., to provide the status of administration of a substance contained therein (e.g., a drug). In an exemplary embodiment, the indicator devices find particular utility within medicament dispensers, such as metered dose inhalers, to provide a visual indication of the status of doses having been or remaining to be administered.

IPC Classes  ?

• A61M 15/00 - Inhalators
• G06M 1/04 - Design features of general application for driving the stage of lowest order
• G06M 1/08 - Design features of general application for actuating the drive
• G06M 1/24 - DrumsDialsPointers
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes

Abstract

The present invention relates to a process for purifying a protein of interest in a batch, integrated continuous or pseudo-continuous mode. Accordingly, the present invention relates to a process for purifying monoclonal antibodies, specifically IgG. in a batch, integrated continuous or pseudo-continuous mode. The process can be executed in batch, continuous, integrated continuous or pseudo-continuous modes.

IPC Classes  ?

• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• C07K 1/18 - Ion-exchange chromatography
• C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Goods & Services

Biological preparations for the treatment of eye conditions, namely, to slow down loss of eye sight due to wet age macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO); Biological preparations for the treatment of eye diseases; Biological preparations for use in intravitreal medicinal therapy; Pharmaceutical preparations for the treatment of wet AMD, DME and RVO; Pharmaceutical preparations for the treatment of eye diseases; Pharmaceutical preparations for slowing the growth of blood vessels in the eye, namely, anti-VEGF intravitreal injections; Pharmaceutical preparations for slowing down blindness due to proliferation of blood vessels in the eye

Goods & Services

Biological preparations for the treatment of eye conditions, namely, to slow down loss of eye sight due to wet age macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO); Biological preparations for the treatment of eye diseases; Biological preparations for use in intravitreal medicinal therapy; Pharmaceutical preparations for the treatment of wet AMD, DME and RVO; Pharmaceutical preparations for the treatment of eye diseases; Pharmaceutical preparations for slowing the growth of blood vessels in the eye, namely, anti-VEGF intravitreal injections; Pharmaceutical preparations for slowing down blindness due to proliferation of blood vessels in the eye

Abstract

The invention relates to a pharmaceutical composition of drospirenone. The pharmaceutical composition exhibits a slow in vitro dissolution rate of drospirenone and does not contain any estrogen.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/50 - Microcapsules

Abstract

The present invention relates to sterile pharmaceutical nanoemulsion ophthalmic composition comprising Brinzolamide, Brimonidine and Bimatoprost useful in the treatment of ocular complications such as glaucoma. The nanoemulsion composition of the invention may also comprise in situ gelling composition with or without preservative(s). The invention also relates to processes for making such compositions.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Goods & Services

pharmaceuticals, namely, contraceptives; oral contraceptives; oral hormonal contraceptives; contraceptive preparations and substances; hormone replacement therapies; hormonal agents for treating disorders and conditions related to women's health, namely, symptoms and conditions associated with menopause, pre-menstruation syndrome and other symptoms and conditions associated with menstruation

Abstract

The present invention relates to a process for producing a recombinant protein in a cell culture medium, comprising culturing mammalian cells expressing the protein of interest in a production medium at suitable conditions; and supplementing the production medium with feed components in such quantity that the residual carbon to nitrogen ratio is controlled. The present invention further relates to a process for producing a recombinant protein in a cell culture medium, wherein recombinant protein of interest has increased acidic variants and/or acidic variants and reduced basic variants.

IPC Classes  ?

• C12N 15/07 - Human cells
• C12P 21/00 - Preparation of peptides or proteins
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

A pharmaceutical composition of low dose Vitamin B12 with one or more pharmaceutically acceptable excipients and methods of making such composition. The invention provides a solid oral pharmaceutical composition of low dose vitamin B12 with an improved content uniformity of vitamin B12 in the composition.

IPC Classes  ?

• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)

Abstract

This disclosure describes an economical and scalable method and process to synthesize the Calcium sensing receptor (CaSR) modulating agent 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates and pharmaceutically acceptable salts therefor. Uses of said intermediates for synthesis of compounds which may be intermediates to the synthesis of 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid are also described herein.

IPC Classes  ?

• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4

Abstract

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients. Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

IPC Classes  ?

• C07D 498/04 - Ortho-condensed systems
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 487/04 - Ortho-condensed systems
• C07D 471/04 - Ortho-condensed systems
• C07D 487/10 - Spiro-condensed systems
• C07D 491/20 - Spiro-condensed systems
• C07D 498/20 - Spiro-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

A solid pharmaceutical composition for oral administration comprising raltegravir or a pharmaceutical acceptable salt thereof, an acidifying agent selected from tartaric acid, citric acid, and fumaric acid, and one or more pharmaceutically acceptable excipients.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Abstract

The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

IPC Classes  ?

• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
• A61P 35/00 - Antineoplastic agents

Abstract

The disclosed invention relates to a stable pharmaceutical composition of varenicline or pharmaceutically acceptable salts thereof. More specifically the disclosed invention relates to a pharmaceutical composition comprising varenicline pharmaceutically acceptable salts thereof with daily acceptable limit of nitrosamine impurities.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

The invention provides for a compound having the structure of Formula (I) to Formula (VI), including Compounds 1 to 6, their pharmaceutically acceptable salts, and compositions comprising thereof. This invention further includes methods of their use for the treatment of diseases or disorders associated with the modulation of calcium sensing receptors (CaSRs), including secondary hyperparathyroidism associated with chronic kidney disease in a subject in need thereof. This disclosure further relates to a process for the preparation of said pharmaceutical compositions.

IPC Classes  ?

• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61P 5/20 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Abstract

A process for manufacturing substituted chroman compounds in an economically scalable manner, without the use of pyrophoric reagents. Also disclosed herein are chroman compound synthesis routes that do not include column chromatography purification steps. The disclosure also relates to the intermediates used in the synthesis. In particular, the disclosure relates to the synthesis of the Calcium sensing receptor (CaSR) modulating agent 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates and pharmaceutically acceptable salts thereof.

IPC Classes  ?

• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4

Abstract

5, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 35/00 - Antineoplastic agents
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Abstract

A stable aqueous pharmaceutical formulation suitable for intravitreal administration comprising a vascular endothelial growth factor (VEGF) specific fusion protein antagonist is provided herein. More particularly a stable aqueous composition comprising a therapeutically effective amount of aflibercept, buffer, bile acid salt and anti-aggregating agent and optionally tonicity modifier wherein, the pH of said formulation is about pH 6.0 to pH 7.0, is provided. Method of making the formulation and its use are also provided.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61K 47/02 - Inorganic compounds

Abstract

The present invention relates to the pharmaceutical composition of anti-tumor necrosis factor agent (anti-TNF agent), preferably etanercept, for management of infectious diseases caused by coronaviruses. The invention further relates to method of administering the therapeutically effective amount of anti-TNF agent alone or in combination with one or more therapeutic agents for management of infectious diseases caused by coronaviruses. The invention also relates to kits comprising the pharmaceutical composition of anti-TNF agent alone or in combination with one or more therapeutic agents.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Abstract

This disclosure relates to pharmaceutical combinations for treating and/or preventing cancer and methods and uses thereof. More particularly, provided are pharmaceutical combination comprising a PRMT5 Inhibitor and a cellular activity modulator selected from an EGFR inhibitor, a KRAS inhibitor, a KRAS-G12C inhibitor, a MEK inhibitor, a Bcl-2 inhibitor, a SOS1 inhibitor, a PARP inhibitor, a RAF inhibitor, a ERK inhibitor, a CDK4/6 inhibitor, a MALT1 inhibitor, a BTK inhibitor, MAT2A inhibitor, a PI3K inhibitor, a AKT inhibitor, a FGFR inhibitor, a Type I PRMT inhibitor, a STING agonist, or an immune checkpoint inhibitor/modulator.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a process for the purification of Fc fusion proteins, wherein the process comprises an affinity chromatography followed by two polishing chromatography steps selected from ion exchange chromatography and mixed mode chromatography, wherein all the chromatography steps are carried out in bind elute mode. The present invention further relates to reducing high mannose species in the purified glycoproteins, comprising contacting glycoprotein solution containing high mannose species with cation exchange resin and eluting the glycoprotein from cation exchange resin to obtain glycoprotein containing lower level of high mannose species.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators

Abstract

The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 487/14 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

The present invention provides a method of treating ocular disorders by administering a suitable amount of VEGF inhibitors in a patient in need thereof, wherein the suitable amount of VEGF inhibitor is determined with respect to the body weight of the patient. Further, present invention also provides a method of treating ocular disorders by administering a personalized dose of a suitable amount of VEGF inhibitors intravitreally, wherein the dose is decided based on the body weight of the said patient at any given point in time.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61P 27/02 - Ophthalmic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form

Goods & Services

(1) Oral contraceptives

Abstract

Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.

IPC Classes  ?

• C07D 498/16 - Peri-condensed systems
• A61P 35/00 - Antineoplastic agents
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Goods & Services

pharmaceuticals, namely, oral contraceptives; oral hormonal contraceptives; contraceptive preparations; hormone replacement therapy preparations; hormonal agents for treating disorders and conditions related to women's health, namely, symptoms and conditions associated with menopause, pre-menstruation syndrome and other symptoms and conditions associated with menstruation; transdermal patches featuring contraceptive preparations

Goods & Services

pharmaceuticals, namely, oral contraceptives; oral hormonal contraceptives; contraceptive preparations; hormone replacement therapy preparations; hormonal agents for treating disorders and conditions related to women's health, namely, symptoms and conditions associated with menopause, pre-menstruation syndrome and other symptoms and conditions associated with menstruation; transdermal patches featuring contraceptive preparations

Goods & Services

pharmaceuticals, namely, oral contraceptives; oral hormonal contraceptives; contraceptive preparations; hormone replacement therapy preparations; hormonal agents for treating disorders and conditions related to women's health, namely, symptoms and conditions associated with menopause, pre-menstruation syndrome and other symptoms and conditions associated with menstruation; transdermal patches featuring contraceptive preparations

Goods & Services

pharmaceuticals, namely, oral contraceptives; oral hormonal contraceptives; contraceptive preparations; hormone replacement therapy preparations; hormonal agents for treating disorders and conditions related to women's health, namely, symptoms and conditions associated with menopause, pre-menstruation syndrome and other symptoms and conditions associated with menstruation

Abstract

This disclosure relates to pharmaceutical combinations for treating and/or preventing cancer and methods and uses thereof. More particularly, provided is a pharmaceutical combination comprising a SOS1 Inhibitor and an additional active ingredient selected from a KRAS inhibitor such as a KRAS G12C inhibitor and a KRAS G12D inhibitor, KRAS G13C inhibitor, and pan KRAS inhibitor; an EGFR inhibitor; an ERK1/2 inhibitor; a BRAF inhibitor; a pan-RAF inhibitor; a MEK inhibitor; a AKT inhibitor; a SHP2 inhibitor; protein arginine methyltransferases (PRMTs) inhibitor such as a PRMTS inhibitor and Type 1 PRMT inhibitor; a PI3K inhibitor; a cyclin -dependent kinase (CDK) inhibitor such as CDK4/6 inhibitor; a FGFR inhibitor; a c-Met inhibitor; a RTK inhibitor; a non-receptor tyrosine kinase inhibitor; a histone methyltransferases (HMTs) inhibitor; a DNA methyltransferases (DNMTs) inhibitor; a Focal Adhesion Kinase (FAK) inhibitor; a Bcr-Abl tyrosine kinase inhibitor; a mTOR inhibitor; a PD1 inhibitor; a PD-L1 inhibitor; CTLA4 inhibitor; and chemotherapeutic agents such as gemcitabine, doxorubicin, cisplatin, carboplatin, paclitaxel, docetaxel, topotecan, irinotecan and temozolomide.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Abstract

This disclosure relates to pharmaceutical combinations for treating and/or preventing cancer and methods and uses thereof. More particularly, provided is a pharmaceutical combination comprising a SOS1 Inhibitor and an additional active ingredient selected from a KRAS inhibitor such as a KRAS G12C inhibitor and a KRAS G12D inhibitor, KRAS G13C inhibitor, and pan KRAS inhibitor; an EGFR inhibitor; an ERK1/2 inhibitor; a BRAF inhibitor; a pan-RAF inhibitor; a MEK inhibitor; a AKT inhibitor; a SHP2 inhibitor; protein arginine methyltransferases (PRMTs) inhibitor such as a PRMTS inhibitor and Type 1 PRMT inhibitor; a PI3K inhibitor; a cyclin -dependent kinase (CDK) inhibitor such as CDK4/6 inhibitor; a FGFR inhibitor; a c-Met inhibitor; a RTK inhibitor; a non-receptor tyrosine kinase inhibitor; a histone methyltransferases (HMTs) inhibitor; a DNA methyltransferases (DNMTs) inhibitor; a Focal Adhesion Kinase (FAK) inhibitor; a Bcr-Abl tyrosine kinase inhibitor; a mTOR inhibitor; a PD1 inhibitor; a PD-L1 inhibitor; CTLA4 inhibitor; and chemotherapeutic agents such as gemcitabine, doxorubicin, cisplatin, carboplatin, paclitaxel, docetaxel, topotecan, irinotecan and temozolomide.

IPC Classes  ?

• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Goods & Services

Inhalers filled with pharmaceutical preparations for the treatment of respiratory ailments Inhalers used for the treatment of respiratory ailments

Abstract

Disclosed herein are novel pharmaceutical compositions of remdesivir or a pharmaceutically acceptable salt thereof suitable for oral administration. The pharmaceutical compositions improve the oral bioavailability of remdesivir and are particularly useful for treatment/or prevention of coronavirus infections.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Disclosed are the macrocyclic compounds having the general Formula (I) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.

IPC Classes  ?

• C07D 498/16 - Peri-condensed systems

Goods & Services

(1) Pharmaceuticals, medical and veterinary preparations namely inhaled pharmaceutical preparations for treating respiratory diseases and disorders; sanitary preparations for medical purposes namely for the treatment of respiratory diseases and disorders; dietetic food and substances adapted for medical and veterinary use namely for the treatment of respiratory diseases and disorders, food for babies; dietary supplements for human beings and animals for general health and well-being; plasters, materials for dressings; material for stopping teeth, dental wax; all-purpose disinfectants; preparations for destroying vermin; fungicides, herbicides.

Goods & Services

(1) Inhaler for dispensing medications

Goods & Services

(1) Inhaler for dispensing medications;

Goods & Services

(1) Pharmaceuticals, medical and veterinary preparations namely inhaled pharmaceutical preparations for treating respiratory diseases and disorders; sanitary preparations for medical purposes namely for the treatment of respiratory diseases and disorders; dietetic food and substances adapted for medical or veterinary use namely for the treatment of respiratory diseases and disorders, food for babies; dietary supplements for human beings and animals for general health and well-being; plasters, materials for dressings; material for stopping teeth, dental wax; all-purpose disinfectants; preparations for destroying vermin; fungicides, herbicides.

Abstract

A precipitation process for amorphous Letermovir, contains residual solvents in accordance with ICH guidelines and is suitable for the preparation of orally administered pharmaceutical formulations. The formulations of the amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of viral diseases, in particular human cytomegalovirus (HCMV) infections.

IPC Classes  ?

• C07D 239/84 - Nitrogen atoms

Abstract

This invention relates to N-nitroso dimethyl amine impurity and more particularly to a novel process for reducing N-nitroso dimethyl amine impurity in pharmaceutical formulations.

IPC Classes  ?

• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 9/28 - DrageesCoated pills or tablets

Abstract

The present invention relates to sterile pharmaceutical nanoemulsion ophthalmic composition comprising Brinzolamide, Brimonidine and Bimatoprost useful in the treatment of ocular complications such as glaucoma. The nanoemulsion composition of the invention may also comprise in situ gelling composition with or without preservative(s). The invention also relates to processes for making such compositions.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

The present invention relates to a stable pharmaceutical composition comprising monoclonal antibody that binds to human epidermal growth factor receptor (EGFR) such as HER2 receptor containing amino acid as a stabilizing excipient and buffer.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

A cost effective and efficient process for separation of cysteinylated or glutathionylated impurities from a therapeutic protein mixture during production of therapeutic protein. In particular, the instant invention provides a separation method of ranibizumab from cysteinylated ranibizumab using anion exchange chromatography.

IPC Classes  ?

• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

RR)-2-amino- 3-phenylpropyl carbamate (APC) by using novel intermediates. (I)

IPC Classes  ?

• C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Abstract

A solid pharmaceutical composition for oral administration comprising raltegravir or its pharmaceutical acceptable salts and pH modifying agent.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Abstract

This disclosure describes an economical and scalable method and process to synthesize the Calcium sensing receptor (CaSR) modulating agent 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates and pharmaceutically acceptable salts therefor. Uses of said intermediates for synthesis of compounds which may be intermediates to the synthesis of 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid are also described herein.

IPC Classes  ?

• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
• C07D 493/10 - Spiro-condensed systems

Abstract

This disclosure describes an economical and scalable method and process to synthesize the Calcium sensing receptor (CaSR) modulating agent 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates and pharmaceutically acceptable salts therefor. Uses of said intermediates for synthesis of compounds which may be intermediates to the synthesis of 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid are also described herein.

IPC Classes  ?

• C07D 311/22 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
• C07D 311/24 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
• C07D 493/10 - Spiro-condensed systems

Abstract

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• C07D 491/20 - Spiro-condensed systems
• C07D 498/04 - Ortho-condensed systems
• C07D 498/20 - Spiro-condensed systems

Abstract

The invention provides for a compound having the structure of Formula (I) to Formula (VI), including Compounds 1 to 6, their pharmaceutically acceptable salts, and compositions comprising thereof. This invention further includes methods of their use for the treatment of diseases or disorders associated with the modulation of calcium sensing receptors (CaSRs), including secondary hyperparathyroidism associated with chronic kidney disease in a subject in need thereof. This disclosure further relates to a process for the preparation of said pharmaceutical compositions.

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61P 5/20 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 498/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The invention provides for a compound having the structure of Formula (I) to Formula (VI), including Compounds 1 to 6, their pharmaceutically acceptable salts, and compositions comprising thereof. This invention further includes methods of their use for the treatment of diseases or disorders associated with the modulation of calcium sensing receptors (CaSRs), including secondary hyperparathyroidism associated with chronic kidney disease in a subject in need thereof. This disclosure further relates to a process for the preparation of said pharmaceutical compositions.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61P 5/20 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 487/04 - Ortho-condensed systems

Abstract

The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Formula (I) wherein, ring A, R1to R5, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 498/04 - Ortho-condensed systems
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Formula (I) wherein, ring A, R1 to R5, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 498/04 - Ortho-condensed systems

Abstract

The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 35/00 - Antineoplastic agents
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or